Future research directions for the use of GLP-1R agonists in the treatment of pain and headache disorders should focus on conducting human trials to evaluate their efficacy and safety, particularly in individuals with comorbid obesity [60]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.